Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Imatinib at 400 mg daily leads to high response rates for chronic-phase CML, but a subset has suboptimal response and/or toxicity. In this study, 846 subjects were randomized to receive nilotinib, a more selective bcr/abl tyrosine kinase inhibitor, at 300 mg BID or 400 mg BID vs. imatinib at 400 mg daily.

Nilotinib vs. Imatinib for Newly Diagnosed CML